CGEM as reported
Cullinan Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 7 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2022 · every figure below is as filed, with no scoring applied
- Net Income
- −$205M
Net Income · −1.0% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2022 · 14 quarters behind |
| Net Income | −$205M | −1.0% | Q2 2026 |
| EPS | −$2.84 | n/a | Q3 2024 · 7 quarters behind |
| ROE | −56% | n/a | Q2 2026 |
| ROA | −51% | n/a | Q2 2026 |
| Free Cash Flow | −$145M | n/a | Q4 2024 · 6 quarters behind |
| P/E | 6.01 | n/a | Q1 2023 · 13 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Cullinan Therapeutics, Inc. (CGEM) - Revenue & ProfitRevenue & ProfitCullinan Therapeutics, Inc. (CGEM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
The closest names by size in the same industry